A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
- Participants will receive treatment with AMG 479 once every three weeks (1 cycle is 3
weeks). AMG 479 is given by intravenous infusion.
- At the beginning of every cycle, participants will have the following procedures:
medical history, physical exam, blood tests and an electrocardiogram (EKG).
- Following every 3 cycles, participants will have the following procedures: blood tests,
an assessment of the tumor by CT scan or MRI and 24-hour urine sample (if applicable).
- Participants may remain in the research study as long as their doctor determines that
they are showing evidence of clinical benefit from the treatment.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the objective response rate associated with AMG 479 in patients with advanced carcinoid or pancreatic neuroendocrine tumors.
Matthew Kulke, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|H. Lee Moffitt Cancer Center||Tampa, Florida 33612|